Valuation : Denali Therapeutics Inc.

Market Cap 3.56B 3.06B 2.88B 2.63B 4.93B 336B 4.94B 34.07B 13.22B 173B 13.37B 13.08B 556B P/E 2026 *
-9.62x
P/E 2027 * -9.66x
Enterprise Value 2.85B 2.45B 2.31B 2.11B 3.95B 269B 3.96B 27.29B 10.59B 138B 10.71B 10.48B 445B EV / Sales 2026 *
56.8x
EV / Sales 2027 * 22.2x
Free-Float
90.03%
Yield 2026 *
-
Yield 2027 * -
1 day-2.28%
1 week-7.17%
Current month-6.23%
1 month-7.82%
3 months+10.63%
6 months+9.38%
Current year+34.95%
1 week 22.14
Extreme 22.145
24.01
1 month 22.14
Extreme 22.145
25.74
Current year 15.34
Extreme 15.34
27.3
1 year 12.58
Extreme 12.58
27.3
3 years 10.57
Extreme 10.57
33.33
5 years 10.57
Extreme 10.57
56.24
10 years 10.57
Extreme 10.57
93.94
Manager TitleAgeSince
Director of Finance/CFO 52 01/05/2022
Chief Executive Officer 50 01/08/2015
Chief Tech/Sci/R&D Officer 58 06/11/2025
Director TitleAgeSince
Director/Board Member 50 01/03/2015
Director/Board Member 73 01/04/2015
Director/Board Member 68 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 A Sell

Founder

-2,768 0.0017%
8/12/26 A Don

Founder

-32,220 0.0203%
8/11/26 A Sell

Founder

-2,857 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
-2.28%-7.17%+50.64%-4.42% 3.56B
-1.79%-2.27%+50.90%+89.03% 67.98B
-2.06%-0.18%+41.53%+88.17% 64.94B
-0.31%+6.54%-11.39%+457.82% 27.58B
-3.00%-2.90%+39.40%+9.41% 25.74B
+0.86%+1.65%+0.25%-14.78% 26.06B
-1.46%+0.42%+24.07%-18.70% 20.09B
-2.96%-15.21%+210.71%+370.84% 17.16B
-1.49%-4.88%-0.41%+530.26% 14.92B
-0.20%+8.37%+57.87%+159.50% 14.62B
Average -1.47%-0.48%+46.36%+166.71% 28.27B
Weighted average by Cap. -1.53%+0.08%+42.40%+143.20%

Financials

2026 *2027 *
Net sales 50.26M 43.24M 40.69M 37.17M 69.53M 4.74B 69.72M 481M 187M 2.43B 189M 185M 7.84B 127M 109M 103M 93.84M 176M 11.98B 176M 1.21B 471M 6.15B 476M 466M 19.8B
Net income -454M -391M -368M -336M -629M -42.91B -630M -4.35B -1.69B -22.02B -1.71B -1.67B -70.92B -453M -389M -366M -335M -626M -42.73B -628M -4.33B -1.68B -21.92B -1.7B -1.66B -70.62B
Net Debt -708M -610M -574M -524M -980M -66.89B -983M -6.78B -2.63B -34.32B -2.66B -2.6B -111B -749M -644M -606M -554M -1.04B -70.69B -1.04B -7.16B -2.78B -36.27B -2.81B -2.75B -117B
Logo Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
Employees
503
Date Price Change Volume
04/09/26 $22.28 -2.28% 799,633
03/09/26 $22.80 -0.22% 1,727,981
02/09/26 $22.85 -1.78% 1,768,603
01/09/26 $23.27 -2.08% 1,431,668
31/08/26 $23.76 -1.00% 985,862
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
22.28USD
Average target price
35.75USD
Spread / Average Target
+60.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DNLI Stock